A protein corona sensor array detects breast and prostate cancers.
Luca DigiacomoKourosh Jafari-KhouzaniSara PalchettiDaniela PozziAnna Laura CapriottiAldo LaganàRiccardo Zenezini ChiozziDamiano CaputoChiara CasconeRoberto CoppolaGerardo FlammiaVittorio AltomareAntonella GrassoMorteza MahmoudiGiulio CaraccioloPublished in: Nanoscale (2021)
Following exposure to human plasma (HP), nanoparticles (NPs) are coated with a biomolecular layer referred to as a protein corona. We recently revealed that characterizing the protein coronas of various NPs may provide a unique opportunity for cancer identification and discrimination. In other words, protein corona profiles of several NPs, when being analyzed using classifiers, would provide a unique "fingerprint" for each type of disease. Here, we probed the capacity of the protein corona for the identification and discrimination of breast and prostate cancer patients from healthy individuals. Using three lipid NP formulations with distinct physical-chemical properties as a cross-reactive sensor array and a supervised random forest classifier, we identified a set of proteins that showed a significant difference in cancer patients and control subjects. Our data show that many of the corona proteins with the highest discrimination ability between oncological patients and healthy individuals are related to cellular and molecular aspects of breast and prostate cancers.
Keyphrases
- amino acid
- end stage renal disease
- binding protein
- chronic kidney disease
- ejection fraction
- machine learning
- newly diagnosed
- mental health
- high throughput
- big data
- physical activity
- peritoneal dialysis
- mass spectrometry
- molecular dynamics simulations
- electronic health record
- lymph node metastasis
- papillary thyroid
- rectal cancer
- neural network
- childhood cancer